Chronic_morphine_therapy_for_cancer_pain:_plasma_and_cerebrospinal_fluid_morphine_and_morphine-6-glucuronide_concentrations._Morphine-6-glucuronide_(M-6-G)_is_an_active_metabolite_that_may_contribute_to_the_clinical_effects_produced_by_systemic_administration_of_morphine._To_help_clarify_the_extent_to_which_M-6-G_may_cross_the_blood-brain_barrier_and_exert_effects,_we_employed_high-performance_liquid_chromatography_with_electrochemical_detection_to_measure_the_concentrations_of_M-6-G_and_morphine_in_the_plasma_and_either_ventricular_(three_patients)_or_lumbar_(eight_patients)_CSF_of_cancer_patients_receiving_chronic_morphine_therapy._The_mean_ratio_of_morphine_in_ventricular_CSF:morphine_in_plasma_was_0.71;_the_same_ratio_for_M-6-G_was_only_0.077._The_average_molar_ratio_of_M-6-G:_morphine_in_ventricular_CSF_was_0.207,_and_the_average_molar_ratio_in_plasma_was_1.89._Although_sampling_problems_render_the_lumbar_CSF_results_less_reliable,_they_were_very_similar._Thus,_plasma_contained_approximately_twice_as_much_M-6-G_as_morphine,_whereas_CSF_contained_only_one-fifth_to_one-third_as_much._These_data_confirm_that_M-6-G_in_plasma_is_distributed_into_CSF,_but_to_a_far_lesser_extent_than_morphine._They_help_explain_animal_data_demonstrating_much_higher_potency_of_M-6-G_on_administration_into_CSF_than_systemic_administration_and_indicate_that_the_degree_to_which_M-6-G_contributes_to_morphine_effects_in_humans_remains_an_unresolved_question.